Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
Title | Inflazome announces acquisition by |
Description | Inflazome announces acquisition by Roche Inflazome is a pioneering inflammasome company developing orally available NLRP3 inflammasome inhibitors to addre |
Keywords | N/A |
WebSite | inflazome.com |
Host IP | 46.22.138.86 |
Location | Ireland |
Site | Rank |
US$1,818,290
Last updated: 2022-09-25 14:23:24
inflazome.com has Semrush global rank of 5,821,022. inflazome.com has an estimated worth of US$ 1,818,290, based on its estimated Ads revenue. inflazome.com receives approximately 209,803 unique visitors each day. Its web server is located in Ireland, with IP address 46.22.138.86. According to SiteAdvisor, inflazome.com is safe to visit. |
Purchase/Sale Value | US$1,818,290 |
Daily Ads Revenue | US$1,679 |
Monthly Ads Revenue | US$50,353 |
Yearly Ads Revenue | US$604,232 |
Daily Unique Visitors | 13,987 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
inflazome.com. | A | 3599 | IP: 46.22.138.86 |
inflazome.com. | NS | 3600 | NS Record: hlrns1.roche.com. |
inflazome.com. | NS | 3600 | NS Record: ns2.roche.com. |
inflazome.com. | NS | 3600 | NS Record: ns1.roche.com. |
inflazome.com. | MX | 3600 | MX Record: 1 inflazome-com.mail.protection.outlook.com. |
inflazome.com. | TXT | 3600 | TXT Record: v=spf1 +ip4:159.134.198.135 include:spf.protection.outlook.com -all |
inflazome.com. | TXT | 3600 | TXT Record: google-site-verification=OB-yCM4v_-Xg2YSAN6uGSv6RULEJlaqz5lm9_d001ZQ |
inflazome.com. | TXT | 3600 | TXT Record: v=verifydomain MS=2429911 |
Inflazome announces acquisition by Roche Inflazome is a pioneering inflammasome company developing orally available NLRP3 inflammasome inhibitors to address clinical unmet needs across a wide variety of inflammatory diseases Acquisition of Inflazome gives Roche full rights to the Inflazome portfolio Activation of the NLRP3 inflammasome in the body is implicated in many diseases caused by chronic, uncontrolled inflammation Inflazome shareholders received €380 million upfront, and are eligible to receive additional milestone payments Dublin (IE), Cambridge (UK), 21 September 2020: Inflazome announced today that it has closed a share purchase agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) in which Inflazome’s shareholders received an upfront payment of €380 million, and are eligible to receive additional contingent payments to be made based on the achievement of certain predetermined milestones. Inflazome was founded in 2016 by leading medical researchers Prof Matt Cooper (University |
HTTP/1.1 302 Found Date: Thu, 13 Jan 2022 08:27:33 GMT Server: Apache Location: http://inflazome.com/press-release-21-sep-2020.html Content-Type: text/html; charset=iso-8859-1 HTTP/1.1 200 OK Date: Thu, 13 Jan 2022 08:27:33 GMT Server: Apache Last-Modified: Mon, 21 Sep 2020 05:59:53 GMT ETag: "1482f-5afcc8f29ecb4" Accept-Ranges: bytes Content-Length: 84015 Vary: Accept-Encoding Content-Type: text/html |
Domain Name: INFLAZOME.COM Registry Domain ID: 2001379348_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.safenames.net Registrar URL: http://www.safenames.net Updated Date: 2020-12-16T07:36:03Z Creation Date: 2016-02-09T06:48:52Z Registry Expiry Date: 2022-02-09T06:48:52Z Registrar: SafeNames Ltd. Registrar IANA ID: 447 Registrar Abuse Contact Email: abuse@safenames.net Registrar Abuse Contact Phone: +44.1908200022 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: HLRNS1.ROCHE.COM Name Server: NS1.ROCHE.COM Name Server: NS2.ROCHE.COM DNSSEC: unsigned >>> Last update of whois database: 2022-01-13T07:28:59Z <<< |